We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Adagio Therapeutics Inc | NASDAQ:ADGI | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.64 | 4.52 | 4.74 | 0 | 01:00:00 |
From May 2021 to May 2024
By Josh Beckerman
Adagio Therapeutics Inc. discussed its efforts related to the Omicron Covid-19 variant, including engaging with the U.S. Food and Drug Administration on potential protocol updates to its global Phase 2/3 clinical trials of ADG20. Updates may include a higher dose.
The company said is pausing enrollment of new patients in the 300-mg dose arm in two clinical trials as it updates protocols.
Adagio also "summarized recent findings reported in three separate publications" that show ADG20, its lead monoclonal antibody, "has neutralization activity against" the Omicron variant.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
January 12, 2022 17:37 ET (22:37 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Adagio Therapeutics Chart |
1 Month Adagio Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
